No certain dose adjustment advised when tofacitinib coadministered with potent CYP2C19 inhibitors; reduce tofacitinib dose if coadministered with both equally moderate CYP3A4 and potent CYP2C19 inhibitors . Nevertheless, the waking system of modafinil is still being absolutely uncovered. Current